Physician profile
Vincent Lee
NPI 1639498462
$15,861.56
in general payments reported to CMS, 2019-2025
45 companies · $2,518 in 2025
The $2,518 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,902 · 2020: $2,027 · 2021: $2,697 · 2022: $2,387 · 2023: $2,320 · 2024: $2,011 · 2025: $2,518.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,767 · Education: $81.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,767.40 |
| Education | $81.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $3,272.75 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $2,664.76 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $1,241.19 | 2019-2025 | Repatha, Repatha, Otezla |
| Abbvie INC. | $1,181.92 | 2020-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,033.95 | 2019-2025 | Trintellix |
| Pfizer INC. | $823.36 | 2019-2025 | |
| Glaxosmithkline, LLC. | $706.26 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $442.82 | 2019-2025 | Xifaxan |
| Biohaven Pharmaceutical Holding Company Ltd. | $373.17 | 2022 | |
| Astellas Pharma US INC | $370.76 | 2019-2025 | Veozah, Myrbetriq |
| Lilly USA, LLC | $328.14 | 2021-2025 | Mounjaro, Zepbound, Emgality |
| Novartis Pharmaceuticals Corporation | $284.42 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $279.33 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $238.77 | 2022-2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $222.66 | 2019-2021 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vincent Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.